Cargando…

Neuromielitis óptica en paciente con virus de inmunodeficiencia humana

BACKGROUND: Neuromyelitis optica spectrum (NMO) is an autoimmune condition with preferential target at the optic nerves and spinal cord. Although HIV infection can also cause neuritis and myelitis, the entity of HIV related to NMO has recently been elucidated, however, little is known about the cont...

Descripción completa

Detalles Bibliográficos
Autores principales: González-Sansores, Erika Elizabeth, Bertado-Cortés, Brenda, León-Castillo, Daniela Alexia, Rubalcava-Sánchez, Nallely
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Instituto Mexicano del Seguro Social 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10396062/
https://www.ncbi.nlm.nih.gov/pubmed/37201182
_version_ 1785083721348546560
author González-Sansores, Erika Elizabeth
Bertado-Cortés, Brenda
León-Castillo, Daniela Alexia
Rubalcava-Sánchez, Nallely
author_facet González-Sansores, Erika Elizabeth
Bertado-Cortés, Brenda
León-Castillo, Daniela Alexia
Rubalcava-Sánchez, Nallely
author_sort González-Sansores, Erika Elizabeth
collection PubMed
description BACKGROUND: Neuromyelitis optica spectrum (NMO) is an autoimmune condition with preferential target at the optic nerves and spinal cord. Although HIV infection can also cause neuritis and myelitis, the entity of HIV related to NMO has recently been elucidated, however, little is known about the context of this disease. OBJECTIVE: To describe the clinical characteristics, imaging, treatment, and functional prognosis in an HIV-positive patient who developed an episode of longitudinally extensive transverse myelitis (LETM) with positive anti-AQP4 antibodies. CLINICAL CASE: 36-year-old man with a history of HIV diagnosed in 2017, on antiretroviral treatment. On March 2021 he was admitted for study due to complete spinal cord syndrome, corroborating in MRI a longitudinally extensive lesion from T8-L1, with CSF with and AQP4 seropositivity, a diagnosis of NMO was integrated by Wingerchuk criteria and rituximab is started with symptomatic improvement, objectifying it with the Expanded Disability Status Scale (EDSS) from 4 to 1. CONCLUSIONS: NMO entity related to HIV is rare, this phenomenon being classically found at the time of diagnosis or after the start of treatment when the immune system is still capable of developing an exaggerated immune response, however in the case we report the debut of NMO occurred 3 years after diagnosis, contrasting with previously reported cases, so we suggest that some other mechanisms could be involved, such as altered regulation of B cells and a direct viral effect.
format Online
Article
Text
id pubmed-10396062
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Instituto Mexicano del Seguro Social
record_format MEDLINE/PubMed
spelling pubmed-103960622023-08-04 Neuromielitis óptica en paciente con virus de inmunodeficiencia humana González-Sansores, Erika Elizabeth Bertado-Cortés, Brenda León-Castillo, Daniela Alexia Rubalcava-Sánchez, Nallely Rev Med Inst Mex Seguro Soc Casos Clínicos BACKGROUND: Neuromyelitis optica spectrum (NMO) is an autoimmune condition with preferential target at the optic nerves and spinal cord. Although HIV infection can also cause neuritis and myelitis, the entity of HIV related to NMO has recently been elucidated, however, little is known about the context of this disease. OBJECTIVE: To describe the clinical characteristics, imaging, treatment, and functional prognosis in an HIV-positive patient who developed an episode of longitudinally extensive transverse myelitis (LETM) with positive anti-AQP4 antibodies. CLINICAL CASE: 36-year-old man with a history of HIV diagnosed in 2017, on antiretroviral treatment. On March 2021 he was admitted for study due to complete spinal cord syndrome, corroborating in MRI a longitudinally extensive lesion from T8-L1, with CSF with and AQP4 seropositivity, a diagnosis of NMO was integrated by Wingerchuk criteria and rituximab is started with symptomatic improvement, objectifying it with the Expanded Disability Status Scale (EDSS) from 4 to 1. CONCLUSIONS: NMO entity related to HIV is rare, this phenomenon being classically found at the time of diagnosis or after the start of treatment when the immune system is still capable of developing an exaggerated immune response, however in the case we report the debut of NMO occurred 3 years after diagnosis, contrasting with previously reported cases, so we suggest that some other mechanisms could be involved, such as altered regulation of B cells and a direct viral effect. Instituto Mexicano del Seguro Social 2023 /pmc/articles/PMC10396062/ /pubmed/37201182 Text en © 2023 Revista Medica del Instituto Mexicano del Seguro Social. https://creativecommons.org/licenses/by-nc-nd/4.0/Esta obra está bajo una Licencia Creative Commons Atribución-NoComercial-SinDerivar 4.0 Internacional.
spellingShingle Casos Clínicos
González-Sansores, Erika Elizabeth
Bertado-Cortés, Brenda
León-Castillo, Daniela Alexia
Rubalcava-Sánchez, Nallely
Neuromielitis óptica en paciente con virus de inmunodeficiencia humana
title Neuromielitis óptica en paciente con virus de inmunodeficiencia humana
title_full Neuromielitis óptica en paciente con virus de inmunodeficiencia humana
title_fullStr Neuromielitis óptica en paciente con virus de inmunodeficiencia humana
title_full_unstemmed Neuromielitis óptica en paciente con virus de inmunodeficiencia humana
title_short Neuromielitis óptica en paciente con virus de inmunodeficiencia humana
title_sort neuromielitis óptica en paciente con virus de inmunodeficiencia humana
topic Casos Clínicos
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10396062/
https://www.ncbi.nlm.nih.gov/pubmed/37201182
work_keys_str_mv AT gonzalezsansoreserikaelizabeth neuromielitisopticaenpacienteconvirusdeinmunodeficienciahumana
AT bertadocortesbrenda neuromielitisopticaenpacienteconvirusdeinmunodeficienciahumana
AT leoncastillodanielaalexia neuromielitisopticaenpacienteconvirusdeinmunodeficienciahumana
AT rubalcavasancheznallely neuromielitisopticaenpacienteconvirusdeinmunodeficienciahumana